LBF20207PG49
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1798 |
| LipidMaps | LMFA03010010 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20207PG49 |
| Prostaglandin H2 | |
|---|---|
| |
| Structural Information | |
| 9α,11α-epidioxy-15S-hydroxy-prosta-5Z,13E-dien-1-oic acid | |
| |
| Formula | C20H32O5 |
| Exact Mass | 352.224974134 |
| Average Mass | 352.46508 |
| SMILES | C(CC[C@H](O)C=C[C@@H]([C@H]21)[C@@H](CC=CCCCC(O)=O)[C@@H](OO2)C1)CC |
| Physicochemical Information | |
| PGH2 was firstly reported as a potent vasoconstrictor. Hamberg_M et al. And PGH2 has been reported as a TP receptor agonist which irreversibly aggregates human platelets at 50-100 ng/ml and also as a suicide substrate for platelet TX synthase proscessing a Ki value of 18 mM . Jones_DA et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
